Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco

American Journal of Public Health

Volumn 92, Issue 3, 2002, Pages 388-394

  Katz, Mitchell H ^a   Schwarcz, Sandra K ^a   Kellogg, Timothy A ^a   Klausner, Jeffrey D ^a   Dilley, James W ^a   Gibson, Steven ^a   McFarland, William ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; GONORRHEA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; SAFE SEX; SEXUAL BEHAVIOR; VIRUS TRANSMISSION;

EID: 0036188036     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.92.3.388     Document Type: Article

References (50)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
3. Sexual transmission of HIV: Infectiousness and prevention
4. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
5. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
6. Effect of antiviral treatment on the shedding of HIV-1 in semen
7. Quantification of HIV in semen: Correlation with antiviral treatment and immune status
8. High viral load in semen of human immunodeficiency virus type-1 infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors
9. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV
10. Effect of highly active antiretrovival therapy on cervicovaginal HIV-1 RNA
11. Effect of antiretrovival therapy on HIV shedding in semen
12. Male-to-female transmission of human T-lymphotropic virus types I and II: Association with viral load
13. Viral load and heterosexual transmission of human immunodeficiency virus type 1
14. Heterosexual HIV-1 transmission and viral load in hemophilic patients
15. Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner
16. Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients
17. Maternal levels of plasma human immunodeficiency virus type-1 RNA and the risk of perinatal transmission
18. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
19. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission
20. Are advances in treatment changing views about high-risk sex?
21. Who may be engaging in high-risk sex due to medical treatment advances?
22. Impact of combination therapies on HIV risk perceptions and sexual risk among HIV-positive and HIV-negative gay and bisexual men
23. Combination therapies for HIV and sexual risk behavior among gay men
24. Protease inhibitor combination therapies and perceptions of gay men regarding AIDS severity and the need to maintain safer sex
25. Sexual behavior changes and protease inhibitor therapy
26. Quality of life in asymptomatic and symptomatic HIV infected persons in a trial of ritonavir/saquinavir therapy
27. Quality of life consequences of adding ritonavir to current antiviral therapy for advanced HIV patients
28. The impact of the 1993 AIDS case definition on the completeness and timeliness of AIDS surveillance
29. Increases in unsafe sex and rectal gonorrhea among men who have sex with men - San Francisco, California, 1994-1997
30. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes
31. Detection of early HIV infection and estimation of HIV incidence using a sensitive/less sensitive testing strategy at anonymous counseling and testing sites in San Francisco
32. Differences in the temporal trends of HIV seroincidence and seroprevalence among sexually transmitted disease clinic patients, 1989-1998: Application of the serologic testing algorithm for recent HIV seroconversion (STARHS)
33. Application of a novel 'detune' HIV EIA to qualify and monitor anti-retroviral therapy trials in patients with early infection
34. Variations in the care of HIV-infected adults in the United States
35. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients
36. Viagra use and sexual risk behaviour among gay men in London
37. Gay men report high rates of unprotected anal sex with partners of unknown or discordant HIV status
38. Continuing high prevalence of HIV and risk behaviors among young men who have sex with men: The Young Men's Survey in the San Francisco Bay Area in 1992 to 1993 and in 1994 to 1995
39. Increase in unprotected anal intercourse with casual partners among Sydney gay men in 1996-98
40. Increase in high risk sexual behavior among homosexual men, London 1996-99: Cross-sectional, questionnaire study
41. Continued high-risk sex among HIV seropositive gay and bisexual men seeking HIV prevention services
42. Resurgent bacterial sexually transmitted disease among men who have sex with men - King County, Washington, 1997-1999
43. Gonorrhea among men who have sex with men - Selected sexually transmitted disease clinics, 1993-1996
44. Outbreak of syphilis among men who have sex with men - Southern California, 2000
45. Rectal gonorrhea as an independent risk factor for HIV infection in a cohort of homosexual men
46. Seroconversion in patients attending sexually transmitted disease clinics
47. Recent increases in HIV seroconversion among repeat anonymous testers in San Francisco
48. A tale of two futures: HIV and antiretroviral therapy in San Francisco
49. Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS
50. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection